← Back to Search

Cannabinoid Receptor Agonist

EHP-101 50 mg BID for Multiple Sclerosis

Phase 2
Waitlist Available
Research Sponsored by Emerald Health Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 28 days, 56 days, 84 days, 112 days, 140 days, 168 days
Awards & highlights

Study Summary

This trial is testing a new drug for safety and effectiveness in adults with relapsing forms of multiple sclerosis.

Eligible Conditions
  • Multiple Sclerosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 28 days, 56 days, 84 days, 112 days, 140 days, 168 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 28 days, 56 days, 84 days, 112 days, 140 days, 168 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence and severity of Treatment Emergent Adverse Events
Secondary outcome measures
Brain lesion activity measured by MRI
Change in blood levels of neurofilament light chain (NfL)
Disability status measured by Expanded Disability Status Scale (EDSS)
+9 more
Other outcome measures
Assessment of white matter diffusivity and integrity measured by Diffusion Tensor Imaging (DTI)
Microstructural analysis and assessment of potential remyelination measured by Magnetization Transfer Ratio (MTR)
Pharmacokinetic profile of VCE-004.8 in terms of area under the plasma concentration-time curve (AUC)
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: EHP-101 Twice a day (BID)Experimental Treatment2 Interventions
Group II: EHP-101 Once a day (OD)Experimental Treatment2 Interventions

Find a Location

Who is running the clinical trial?

Emerald Health PharmaceuticalsLead Sponsor
2 Previous Clinical Trials
140 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
2021. "Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04909502.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top